Zachary Zimmerman, Ph.D. is a founder and CEO of Forge Therapeutics and leads business functions including corporate development, strategic planning, business operations and finance. Dr. Zimmerman has over 15 years of biotechnology start-up experience holding various business and scientific positions at Arcturus Therapeutics, Regulus Therapeutics, Alnylam Pharmaceuticals, and 454 Life Sciences. He brings both practical and strategic senior management experience to Forge Therapeutics and is a proven and capable leader who can build and motivate teams to achieve great results. Dr. Zimmerman has successfully driven company growth through strategic alliances, financings and non-dilutive grant awards. He has led and supported several business transactions including the Regulus Therapeutics initial public offering raising $80.9M in gross proceeds. Additional strategic activities include the business development efforts for multiple therapeutic alliances with large biopharma such as Astra Zeneca, Sanofi, GSK, Biogen, Takeda, Kyowa Hakko and Cubist totaling $3.2B with over $200M in upfront cash payments. Dr. Zimmerman has also led the strategic planning and execution of over $70M in non-dilutive grant funding from the Federal Government (NIH, DOD, DARPA, DTRA, and BARDA) and medical research foundations including the Cystic Fibrosis Foundation, Michael J. Fox Foundation, and Accelerate Brain Cancer Cures. Dr. Zimmerman is a trained cellular biologist with expertise in drug discovery and development. He was a post-doctoral fellow at Stanford University School of Medicine and earned his Ph.D. in Molecular, Cellular, and Developmental Biology at University of California, Santa Cruz. Other previous experience includes research at The Scripps Research Institute, and sales and marketing at Mediatech, Inc.